Immunosorbent method for the detection of A, B, O blood group specificity on CEA preparations.
Explore the source record for details and available documents.
ABO Blood-Group System↗
Biomedical subjects
R Magous
Publications and source records attributed to R Magous.
Presence of blood group H antigen on a carcinoembryonic antigen, and its enzymatic modification into blood group A and B specificities.
A carcinoembryonic antigen (CEA-M) was purified from a hepatic metastasis obtained from a blood group O patient with cancer of the rectum. Using 125I-labeled carcinoembryonic antigen (CEA) and blood group antisera, H specificity has been found on the CEA-M. As the addition of anti-H to anti-CEA does not modify the extent of binding of labeled CEA-M to its antibodies (86%), the H and CEA determinants are carried by the same molecule. The affinity chromatography of CEA-M on an immunosorbent "anti-H-Sepharose" demonstrated that a proportion of CEA-M molecules might bear both H and CEA antigenic determinants. In addition, glycosyltransferases were used to modify the blood group H specificity into blood group A or B specificities.
ABO Blood-Group System↗
[Presence of the H blood group antigen on a carcinoembryonic antigen (CEA). Enzymatic transformation of H to A and B specificities].
The carcinoembryonic antigen (CEA-M) was purified from a hepatic metastasis obtained from a blood group O patient with a cancer of the rectum. Using 125I-labelled-CEA and blood group antisera, H specificity was found on the CEA-M; the addition of anti-H to anti-CEA does not modify the binding of labelled-CEA-M to its antibodies (86%), this result leads us to conclude that H and CEA determinants are carried by the same molecule. However the low percentage of binding (30% with 1/10 anti-H) suggests that only a few CEA-M molecules do carry the H antigenic determinant. Finally, glycosyltransferases were used to modify the H specificity into blood group A and B specificities.
ABO Blood-Group System↗
Enzymatic modification of the transplant antigens (ABO system) on human tumor cells.
Blood group glycosyltransferases were used to modify HeLa cells of H specificity (O Group) into cells of A and B specificity. We also obtained the identical type of modification with lymphocytes from healthy subjects and leukemia patients. This method can be applied to tumor cells in general, and constitutes an attempt to stimulate the immunocompetent system.
ABO Blood-Group System↗